Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIJEX vs CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Management of secondary hyperparathyroidism in patients with chronic kidney disease stage 3, 4, and 5 on dialysis,Hypocalcemia in patients with hypoparathyroidism,Hypocalcemia in renal osteodystrophy,Off-label: treatment of hypocalcemia due to pseudohypoparathyroidism or vitamin D-dependent rickets
Treatment of plaque psoriasis (FDA-approved)
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate).
Primarily hepatic via 24-hydroxylation; also undergoes further oxidation and conjugation. Not significantly metabolized by CYP450 enzymes.
Calcipotriene undergoes hepatic metabolism primarily via cytochrome P450 (CYP) enzymes, including CYP24A1. Betamethasone dipropionate is metabolized in the liver via CYP3A4.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites.
Approximately 99.9% bound to vitamin D-binding protein (DBP) and albumin.
Calcipotriene: ~94% bound to plasma proteins; betamethasone dipropionate: ~64% bound (predominantly albumin).
Volume of distribution (Vd) is approximately 0.25 L/kg (range 0.2-0.3 L/kg). This low Vd indicates distribution mainly to extracellular fluid and tissues.
Calcipotriene: >1 L/kg (extensive tissue distribution); betamethasone dipropionate: not well characterized, likely large due to lipophilicity.
Oral bioavailability is approximately 60-70% when administered as the injectable formulation orally; however, for IV administration, bioavailability is 100%.
Topical: minimal systemic absorption (<1% for calcipotriene, ~10-15% for betamethasone dipropionate via inflamed skin).
For GFR < 30 m L/min: reduce initial dose to 0.25 mcg oral or 0.5 mcg IV three times weekly. No adjustment for GFR > 30 m L/min.
No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment due to potential for systemic absorption.
No specific recommendations for Child-Pugh classes; caution in severe hepatic impairment due to risk of accumulation.
No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment due to potential for systemic corticosteroid effects.
Intravenous: 0.01-0.05 mcg/kg three times weekly; titrate based on calcium and PTH levels. Oral: 0.015-0.025 mcg/kg once daily.
Safety and efficacy in children <12 years have not been established. For children ≥12 years, apply once daily to affected areas, limit use to <30 g/week, and avoid prolonged use.
Start at low end of dosing range (0.25 mcg oral or 0.25-0.5 mcg IV three times weekly); monitor calcium and phosphate closely due to increased sensitivity.
No specific dose adjustment required, but use with caution due to increased risk of skin atrophy and systemic effects. Avoid prolonged use and apply to limited areas.
None
None.
Hypercalcemia, hypercalciuria, hyperphosphatemia; aluminum hydroxide use may increase aluminum absorption; avoid vitamin D supplementation; monitor serum calcium and phosphate levels regularly; caution in patients with coronary artery disease (calcium load).
Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.,Local adverse reactions may include skin atrophy, striae, telangiectasias, burning, pruritus, folliculitis, and allergic contact dermatitis.,May cause hypercalcemia and hypercalciuria due to calcipotriene component; monitor serum and urine calcium levels in patients with renal impairment or high doses.,Avoid use on face, groin, axillae, or intertriginous areas due to increased risk of adverse effects.,Not recommended for long-term continuous use due to potential for skin atrophy and systemic effects.
Hypercalcemia, vitamin D toxicity, known hypersensitivity to calcitriol or any component of the formulation.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any component of the formulation.,Patients with known calcium metabolism disorders (e.g., hypercalcemia, vitamin D toxicity).,Patients with known or suspected skin infections, including viral (e.g., herpes simplex, varicella), fungal, or bacterial infections.,Use on eroded, ulcerated, or exudative skin.
Avoid excessive dietary calcium (dairy products, fortified foods) during treatment. Do not take calcium-containing antacids or supplements. Maintain adequate fluid intake to prevent hypercalcemia.
No significant food interactions. No dietary restrictions necessary for this topical medication.
Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data are limited. Pregnancy Category C. First trimester: Theoretical risk of teratogenicity if hypercalcemia occurs; avoid excessive doses. Second and third trimesters: Risk of fetal hypercalcemia and suppression of parathyroid function if maternal hypercalcemia develops; use only if clearly needed and monitor maternal calcium levels.
Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show increased risk of cleft palate and fetal growth restriction. In humans, first-trimester use of potent corticosteroids is associated with a small increased risk of oral clefts (OR 1.5). Second/third trimester: Prolonged use may cause fetal adrenal suppression and low birth weight. Avoid application to large areas (>30% BSA) or under occlusion.
Calcitriol is excreted into human breast milk but in low amounts. No adverse effects reported in nursing infants. The M/P ratio is not established. Caution is advised due to risk of hypercalcemia in the infant; monitor infant serum calcium if maternal use is necessary.
Minimal systemic absorption after topical use. No specific M/P ratio available. Exercise caution: avoid application to breast area to prevent infant ingestion. Monitor infant for signs of adrenal suppression (rare). Use lowest effective dose for shortest duration.
Dosing adjustments may be required due to altered calcium metabolism in pregnancy. Increase in glomerular filtration rate (GFR) and expanded plasma volume may increase clearance, potentially requiring higher doses. However, maintain normocalcemia; monitor serum calcium and adjust dose accordingly. Starting dose typically unchanged but may need titration based on calcium levels.
No dose adjustment needed for topical use. However, restrict application to <30% body surface area and avoid prolonged treatment; use shortest possible duration. Systemic absorption may increase with psoriatic skin barrier disruption; monitor for corticosteroid side effects.
Monitor serum calcium and phosphate levels closely; hypercalcemia risk is highest with concurrent thiazide use or high calcium intake. Adjust dose based on PTH levels in CKD patients. Use with caution in digitalis-treated patients due to additive positive inotropic effect.
Apply only to psoriatic plaques, not to normal skin or flexures. Maximum weekly dose: 100g. Avoid occlusion. Use with caution on face, genitals, and intertriginous areas due to risk of corticosteroid atrophy. Discontinue if hypersensitivity develops. Monitor for hypercalcemia if used on extensive areas. Not recommended for use in children under 18 years.
Take this medication exactly as prescribed; do not change dose or frequency without consulting your doctor.,Alert your doctor if you experience symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid excessive intake of calcium-rich foods, supplements, or antacids during treatment.,You may need regular blood tests to monitor calcium, phosphate, and parathyroid hormone levels.,Inform all healthcare providers that you are taking Calcijex.
For external use only.,Apply once daily to psoriatic lesions only, avoiding unaffected skin.,Do not use more than 100 grams per week.,Do not cover with bandages or tight dressings.,Wash hands after application unless treating hands.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use on face, armpits, or groin unless directed.,Inform your healthcare professional if you experience burning, itching, or skin thinning.,Use only on children under 18 if specifically prescribed.,Do not use for more than 4 weeks without medical evaluation.
No interactions on record
"Coadministration of Betamethasone, a potent corticosteroid, may reduce the therapeutic efficacy of Miglustat, a glucosylceramide synthase inhibitor used for Gaucher disease and Niemann-Pick type C. Betamethasone can induce hepatic CYP3A4 isoenzymes, potentially increasing the metabolism of Miglustat, though Miglustat is primarily renally excreted and not extensively metabolized. The interaction may also involve corticosteroid-mediated alterations in drug transport or GlcCer synthesis pathways, leading to decreased Miglustat plasma concentrations and diminished clinical response, including worsening of neurological symptoms in Niemann-Pick disease."
"Concomitant use of betamethasone, a corticosteroid, with donepezil, a cholinesterase inhibitor used in Alzheimer's disease, may increase the risk of gastrointestinal adverse effects including gastric ulceration and hemorrhage. Corticosteroids inhibit prostaglandin synthesis and mucosal protection, while donepezil enhances cholinergic tone, increasing gastric acid secretion. This additive effect on the gastric mucosa can lead to clinically significant ulcer formation or gastrointestinal bleeding, particularly in elderly patients."
"Betamethasone, a potent corticosteroid, can induce hyperglycemia and dyslipidemia, potentially counteracting the lipid-lowering effects of atorvastatin. Concurrent use may increase the risk of corticosteroid-related adverse effects such as fluid retention, hyperglycemia, and myopathy. Atorvastatin may also increase systemic exposure to corticosteroids via inhibition of CYP3A4, though this interaction is generally not clinically significant."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIJEX vs CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, answered by our medical review team.
CALCIJEX is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIJEX and CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIJEX is: Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.. The standard adult dose of CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is: Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIJEX and CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIJEX is classified as Category C. Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data a. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is classified as Category C. Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.